Equities

Standard BioTools Inc

Standard BioTools Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.11
  • Today's Change0.08 / 3.94%
  • Shares traded28.00
  • 1 Year change-26.74%
  • Beta1.5816
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Standard BioTools Inc grew revenues 8.57% from 97.95m to 106.34m while net income improved from a loss of 190.10m to a smaller loss of 74.66m.
Gross margin46.67%
Net profit margin-87.05%
Operating margin-93.94%
Return on assets-22.29%
Return on equity-82.98%
Return on investment-26.55%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Standard BioTools Inc fell by 29.83m. However, Cash Flow from Investing totalled 20.24m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 43.29m for operations while cash used for financing totalled 6.81m.
Cash flow per share-0.7159
Price/Cash flow per share--
Book value per share1.37
Tangible book value per share1.02
More ▼

Balance sheet in USDView more

Standard BioTools Inc has a Debt to Total Capital ratio of 9.74%, a lower figure than the previous year's 30.66%.
Current ratio3.88
Quick ratio3.53
Total debt/total equity0.108
Total debt/total capital0.0974
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.